Enhanced Cytotoxic Effect of Doxorubicin Conjugated to Glutathione-Stabilized Gold Nanoparticles in Canine Osteosarcoma-In Vitro Studies

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2021 Jul 2

PMID 34201296

Citations 11

Authors

Anna Malek

Bartlomiej Taciak

Katarzyna Sobczak

Agnieszka Grzelak

Michal Wojcik

Jozef Mieczkowski

Roman Lechowski

Katarzyna A Zabielska-Koczywas

Affiliations

Soon will be listed here.

Abstract

Osteosarcoma (OSA) is the most common malignant bone neoplasia in humans and dogs. In dogs, treatment consists of surgery in combination with chemotherapy (mostly carboplatin and/or doxorubicin (Dox)). Chemotherapy is often rendered ineffective by multidrug resistance. Previous studies have revealed that Dox conjugated with 4 nm glutathione-stabilized gold nanoparticles (Au-GSH-Dox) enhanced the anti-tumor activity and cytotoxicity of Dox in Dox-resistant feline fibrosarcoma cell lines exhibiting high P-glycoprotein (P-gp) activity. The present study investigated the influence of Au-GSH-Dox on the canine OSA cell line D17 and its relationship with P-gp activity. A human Dox-sensitive OSA cell line, U2OS, served as the negative control. Au-GSH-Dox, compared to free Dox, presented a greater cytotoxic effect on D17 (IC values for Au-GSH-Dox and Dox were 7.9 μg/mL and 15.2 μg/mL, respectively) but not on the U2OS cell line. All concentrations of Au-GSH (ranging from 10 to 1000 μg/mL) were non-toxic in both cell lines. Inhibition of the D17 cell line with 100 μM verapamil resulted in an increase in free Dox but not in intracellular Au-GSH-Dox. The results indicate that Au-GSH-Dox may act as an effective drug in canine OSA by bypassing P-gp.

Citing Articles

Exosomes in Bone Cancer: Unveiling their Vital Role in Diagnosis, Prognosis, and Therapeutic Advancements.

Ghosh S, Mahajan A, Dey A, Rajendran R, Chowdhury A, Sen S J Cancer. 2024; 15(13):4128-4142.

PMID: 38947401 PMC: 11212077. DOI: 10.7150/jca.95709.

PEG-liposomal doxorubicin as a potential agent for canine metastatic osteosarcoma - and studies.

Walewska M, Malek A, Taciak B, Wojtalewicz A, Wilk S, Wojtkowska A J Vet Res. 2023; 67(2):297-305.

PMID: 37786430 PMC: 10541662. DOI: 10.2478/jvetres-2023-0026.

Meeting Contemporary Challenges: Development of Nanomaterials for Veterinary Medicine.

Danchuk O, Levchenko A, da Silva Mesquita R, Danchuk V, Cengiz S, Cengiz M Pharmaceutics. 2023; 15(9).

PMID: 37765294 PMC: 10536669. DOI: 10.3390/pharmaceutics15092326.

Gold Nanoparticles Inhibit Extravasation of Canine Osteosarcoma Cells in the Ex Ovo Chicken Embryo Chorioallantoic Membrane Model.

Malek A, Wojnicki M, Borkowska A, Wojcik M, Ziolek G, Lechowski R Int J Mol Sci. 2023; 24(12).

PMID: 37373007 PMC: 10297960. DOI: 10.3390/ijms24129858.

Nanocarriers in Veterinary Medicine: A Challenge for Improving Osteosarcoma Conventional Treatments.

Sapino S, Chindamo G, Chirio D, Morel S, Peira E, Vercelli C Nanomaterials (Basel). 2022; 12(24).

PMID: 36558354 PMC: 9785518. DOI: 10.3390/nano12244501.

References

Petriz J, Garcia-Lopez J . Flow cytometric analysis of P-glycoprotein function using rhodamine 123. Leukemia. 1997; 11(7):1124-30. DOI: 10.1038/sj.leu.2400659. View

Cheng J, Gu Y, Cheng S, Wong W . Surface functionalized gold nanoparticles for drug delivery. J Biomed Nanotechnol. 2013; 9(8):1362-9. DOI: 10.1166/jbn.2013.1536. View

Zabielska-Koczywas K, Wojtalewicz A, Uzarowska E, Klejman A, Wojtkowska A, Dolka I . Distribution of Glutathione-Stabilized Gold Nanoparticles in Feline Fibrosarcomas and Their Role as a Drug Delivery System for Doxorubicin-Preclinical Studies in a Murine Model. Int J Mol Sci. 2018; 19(4). PMC: 5979397. DOI: 10.3390/ijms19041021. View

Zekri J, Mansour M, Karim S . The anti-tumour effects of zoledronic acid. J Bone Oncol. 2016; 3(1):25-35. PMC: 4723416. DOI: 10.1016/j.jbo.2013.12.001. View

Qin M, Lee Y, Ray A, Kopelman R . Overcoming cancer multidrug resistance by codelivery of doxorubicin and verapamil with hydrogel nanoparticles. Macromol Biosci. 2014; 14(8):1106-15. DOI: 10.1002/mabi.201400035. View

MacEwen E, Kurzman I, Rosenthal R, Smith B, Manley P, Roush J . Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide. J Natl Cancer Inst. 1989; 81(12):935-8. DOI: 10.1093/jnci/81.12.935. View

Boston S, Ehrhart N, Dernell W, Lafferty M, Withrow S . Evaluation of survival time in dogs with stage III osteosarcoma that undergo treatment: 90 cases (1985-2004). J Am Vet Med Assoc. 2006; 228(12):1905-8. DOI: 10.2460/javma.228.12.1905. View

Simpson C, Salleng K, Cliffel D, Feldheim D . In vivo toxicity, biodistribution, and clearance of glutathione-coated gold nanoparticles. Nanomedicine. 2012; 9(2):257-63. DOI: 10.1016/j.nano.2012.06.002. View

Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N . Drug resistance in cancer: an overview. Cancers (Basel). 2014; 6(3):1769-92. PMC: 4190567. DOI: 10.3390/cancers6031769. View

10.

MacDonald V . Chemotherapy: managing side effects and safe handling. Can Vet J. 2009; 50(6):665-8. PMC: 2684058. View

11.

Chavanpatil M, Khdair A, Gerard B, Bachmeier C, Miller D, Shekhar M . Surfactant-polymer nanoparticles overcome P-glycoprotein-mediated drug efflux. Mol Pharm. 2007; 4(5):730-8. DOI: 10.1021/mp070024d. View

12.

Kang J, Cho H, Lee H, Jin H, Maeng H . Polyethylene glycol-decorated doxorubicin/carboxymethyl chitosan/gold nanocomplex for reducing drug efflux in cancer cells and extending circulation in blood stream. Int J Biol Macromol. 2018; 125:61-71. DOI: 10.1016/j.ijbiomac.2018.12.028. View

13.

Aszalos A, Thompson K, Yin J, Ross D . Combinations of P-glycoprotein blockers, verapamil, PSC833, and cremophor act differently on the multidrug resistance associated protein (MRP) and on P-glycoprotein (Pgp). Anticancer Res. 1999; 19(2A):1053-64. View

14.

Selmic L, Burton J, Thamm D, Withrow S, Lana S . Comparison of carboplatin and doxorubicin-based chemotherapy protocols in 470 dogs after amputation for treatment of appendicular osteosarcoma. J Vet Intern Med. 2014; 28(2):554-63. PMC: 4857984. DOI: 10.1111/jvim.12313. View

15.

Mason N, Gnanandarajah J, Engiles J, Gray F, Laughlin D, Gaurnier-Hausser A . Immunotherapy with a HER2-Targeting Listeria Induces HER2-Specific Immunity and Demonstrates Potential Therapeutic Effects in a Phase I Trial in Canine Osteosarcoma. Clin Cancer Res. 2016; 22(17):4380-90. DOI: 10.1158/1078-0432.CCR-16-0088. View

16.

Bobo D, Robinson K, Islam J, Thurecht K, Corrie S . Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date. Pharm Res. 2016; 33(10):2373-87. DOI: 10.1007/s11095-016-1958-5. View

17.

Gramer I, Kessler M, Geyer J . Determination of MDR1 gene expression for prediction of chemotherapy tolerance and treatment outcome in dogs with lymphoma. Vet Comp Oncol. 2013; 13(4):363-72. DOI: 10.1111/vco.12051. View

18.

Lasagna-Reeves C, Gonzalez-Romero D, Barria M, Olmedo I, Clos A, Ramanujam V . Bioaccumulation and toxicity of gold nanoparticles after repeated administration in mice. Biochem Biophys Res Commun. 2010; 393(4):649-55. DOI: 10.1016/j.bbrc.2010.02.046. View

19.

Dow S, Elmslie R, Kurzman I, MacEwen G, Pericle F, Liggitt D . Phase I study of liposome-DNA complexes encoding the interleukin-2 gene in dogs with osteosarcoma lung metastases. Hum Gene Ther. 2005; 16(8):937-46. DOI: 10.1089/hum.2005.16.937. View

20.

Tacar O, Sriamornsak P, Dass C . Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol. 2013; 65(2):157-70. DOI: 10.1111/j.2042-7158.2012.01567.x. View